A5075707106- Peptidase Inhibition and Analysis
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Prostate Cancer Treatment and Research
- Protease and Inhibitor Mechanisms
- Cardiac Structural Anomalies and Repair
- Prostate Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Neutropenia and Cancer Infections
- Medical Imaging and Pathology Studies
- Glioma Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Breast Cancer Treatment Studies
- Neuropeptides and Animal Physiology
- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Cardiac Imaging and Diagnostics
- HER2/EGFR in Cancer Research
- Neuroendocrine Tumor Research Advances
- Soft tissue tumor case studies
- S100 Proteins and Annexins
- Pancreatic and Hepatic Oncology Research
- Vascular anomalies and interventions
- Central Venous Catheters and Hemodialysis
German Breast group
2023-2025
University of Duisburg-Essen
2020-2024
Essen University Hospital
2020-2024
Deutschen Konsortium für Translationale Krebsforschung
2020-2024
Düsseldorf University Hospital
2024
Heinrich Heine University Düsseldorf
2024
German Cancer Research Center
2023
West German Heart and Vascular Center Essen
2023
Klinik und Poliklinik für Nuklearmedizin
2020-2023
King Hussein Cancer Center
2017-2021
Fibroblast activation protein (FAP) is overexpressed in several solid tumors and therefore represents an attractive target for radiotheranostic applications. Recent investigations demonstrated rapid high uptake of small-molecule inhibitors FAP (68Ga-FAPI-46) PET imaging. Here, we report our initial experience the feasibility safety 90Y-FAPI-46 radioligand therapy extensively pretreated patients with tumors. Methods: Patients were considered if they showed both exhaustion all approved...
Fibroblast activation protein inhibitor (FAPI) PET/CT is a new tool in the diagnostic workup of cancer. With growing volume applications, pitfalls and common findings need to be considered for 68Ga-FAPI image interpretation. The aim this study was summarize report PET/CT. Methods: Ninety-one patients underwent whole-body with either FAPI-04 (n = 25) or FAPI-46 66). Findings were rated consensus session 2 experienced readers. Pitfalls defined as focal localized uptake above background level...
<b>Introduction:</b> Bone and soft tissue sarcomas express fibroblast activation protein (FAP) on tumor cells associated fibroblast. Therefore, FAP is a promising therapeutic diagnostic target. Novel radio-labelled FAP-Inhibitors (e.g. <sup>68</sup>Ga-FAPI46) have shown high uptake in positron emission tomography (PET) sarcoma patients. Here we report endpoints of the FAPI-PET prospective observational trial. <b>Methods:</b> Forty-seven patients with bone or undergoing clinical...
The aim of this retrospective analysis was to examine the pattern cardiac 68Ga-fibroblast-activation protein-α inhibitor (FAPI) uptake in patients after acute myocardial infarction (AMI) using PET and investigate its association with results coronary angiography. We correlated FAPI biomarkers damage including left ventricular function.A cohort 10 no history artery disease underwent 18 ± 20.6 days AMI (ST-segment elevation [n = 5] non-ST-segment 5]), respectively. SUVmax, SUVmean, SUVpeak...
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and third frequent cause of cancer-related death. A growing number local systemic therapies are available, accurate staging critical for management decisions. We assessed impact neovasculature imaging by <sup>68</sup>Ga-PSMA-11 PET/CT on disease staging, prognostic groups, patients with HCC compared CT. <b>Methods:</b> Forty who received between September 2018 2019 were retrospectively included. Management before after PET...
Management of cholangiocarcinoma is among other factors critically determined by accurate staging. Here, we aimed to assess the accuracy PET/CT with novel cancer fibroblast–directed <sup>68</sup>Gafibroblast activation protein (FAP) inhibitor (FAPI)-46 tracer for staging and management guidance. <b>Methods:</b> Patients from a prospective observational trial were analyzed. <sup>68</sup>Ga-FAPI-46 detection efficacy was compared <sup>18</sup>F-FDG conventional CT....
To assess the diagnostic accuracy of <sup>68</sup>Ga-labeled fibroblast activation protein inhibitor (FAPI) and <sup>18</sup>F-labeled FDG PET for detection various tumors, we performed a head-to-head comparison both imaging modalities across range tumor entities as part our ongoing <sup>68</sup>Ga-FAPI observational trial. <b>Methods:</b> The study included 115 patients with 8 who received staging or restaging between October 2018 March 2022. Of those, 103 concomitant <sup>18</sup>F-FDG had...
Fibroblast activation protein-α (FAP) is often highly expressed by sarcoma cells and sarcoma-associated fibroblasts in the tumor microenvironment. This makes it a promising target for imaging therapy. The level of FAP expression diagnostic value
Tumoral fibroblast activation protein expression is associated with proliferation and angiogenesis can be visualized by PET/CT. We examined the prognostic value of [
Positron emission tomography (PET) using small ligands of the fibroblast activation protein (FAP) was recently introduced. However, optimal uptake time has not been defined yet. Here, we systematically compare early (~ 10 min p.i.) and late 60 FAPI-46 imaging in patients with various types cancer.This is a retrospective single-institutional study. Imaging performed at Essen University Hospital, Germany. A total 69 who underwent dual time-point for either restaging (n = 52, 75%) or staging...
The fibroblast activation protein (FAP) is highly expressed on carcinoma-associated fibroblasts in the stroma of pancreatic cancer and thus a promising target for imaging therapy. Preliminary data PET with radiolabeled FAP inhibitors (FAPIs) demonstrate superior tumor detection. Here we assess accuracy FAP-directed patients cancer. <b>Methods:</b> Of 64 suspected or proven cancer, 62 (97%) were included analysis <sup>68</sup>Ga-FAPI observational trial (NCT04571086). All these underwent...
Abstract Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (Her2 − ) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly improves outcomes for HR , Her2 and -mutated metastatic BC patients. However, acquired resistance, often due aberrant activation mTOR complex 1 (mTORC1) pathway, remains a significant clinical...
Despite the recent progress in development of anti-cancer drugs, treatment metastatic tumors is usually ineffective. The systemic inflammatory response performs key roles different stages carcinogenesis process including metastasis. high neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte (MLR), and platelet-lymphocyte (PLR) were found to be associated with poor survival rates majority solid tumors. However, only a few studies conducted further investigate this association patients...
Abstract Background Staging of non-small-cell lung cancer (NSCLC) is a multidisciplinary process involving imaging, endoscopic and surgical techniques. This study aims at investigating the diagnostic accuracy 18 F-FDG PET/CT, CT scan, endobronchial ultrasound/transbronchial needle aspirate (EBUS/TBNA) in preoperative mediastinal lymph nodes (MLNs) staging NSCLC. Methods We identified all patients who were diagnosed with NSCLC King Hussein Cancer Center Amman, Jordan, between July 2011...
This multicenter randomized phase III trial (NCT04457245) evaluated the effect of performing prostate-specific membrane antigen (PSMA) PET/CT before definitive radiotherapy.
Prostate-specific membrane antigen (PSMA)–ligand PET is potentially useful for screening of castration-resistant prostate cancer (CRPC) clinical trial target populations. We investigated the impact PSMA on Prostate Cancer Clinical Trials Working Group 3 (PCWG3) subtype classification when compared with conventional imaging (CI). <b>Methods:</b> A multicenter retrospective study enrolled patients who had undergone CRPC, prostate-specific values at least 1 ng/mL, and CI—that is, CT plus bone...
Definitive radiation therapy (dRT) is an effective initial treatment of intermediate-risk (IR) and high-risk (HR) prostate cancer (PCa). PSMA PET/CT superior to standard care imaging (CT, MRI, bone scan) for detecting regional distant metastatic PCa. thus has the potential guide patient selection planning dRT improve outcomes.
This phase II study evaluated the impact of adding ribociclib to maintenance endocrine therapy (ET) treatment physicians' choice following first palliative chemotherapy in pre- and post-menopausal women with hormone receptor positive (HR+)/human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (mBC).